- ASSOCIATE PROFESSOR Psychiatry
- ASSOCIATE PROFESSOR Pediatrics
Child & Adolescent Psychiatry
Psychiatry, American Board of Psychiatry and Neurology
MD, Sackler School of Medicine
Mount Sinai School of Medicine
Fellowship, Child and Adolescent Psychiatry
Mount Sinai Hospital
Teacher of the Year Award in Child and Adolescent Psychiatry
AACAP Outstanding Mentor Award
Excellence in Teaching Award
AAP Junior Faculty Development Award
AACAP Pilot Research Award
Richard L. Scharf Memorial Award for Teaching Excellence
NIMH Outstanding Resident Award
Teacher of the Year Award
Alpha Omega Alpha (AOA)
Dr. Kolevzon's research interests include the biological causes and effective treatment of autism and related pervasive developmental disorders. He is also committed to medical student and residency training and education and interested in developing innovative educational programs.
Soorya L, Kolevzon A, Zweifach J, Lim T, Dobry Y, Schwartz L, Frank Y, Wang AT, Cai G, Parkhomenko E, Halpern D, Grodberg D, Angarita B, Willner JP, Yang A, Canitano R, Chaplin W, Betancur C, Buxbaum JD. Prospective investigation of autism and genotype-phenotype correlations in 22q13 deletion syndrome and SHANK3 deficiency. Molecular autism 2013; 4(1).
Stein JA, Althoff R, Anders T, Davison Y, Edwards S, Frosch E, Horst R, Hudziak JJ, Hunt J, Joshi SV, Kitts RL, Larson J, Leckman J, O'Brien J, Lowenhaupt E, Pruitt D, Malloy E, Martin A, Partner A, Sarles R, Sikich L, Wells L, Kolevzon A. Does early mentorship in child and adolescent psychiatry make a difference? The Klingenstein Third-Generation Foundation Medical Student Fellowship Program. Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry 2013 Sep; 37(5).
Sandin S, Hultman CM, Kolevzon A, Gross R, MacCabe JH, Reichenberg A. Advancing maternal age is associated with increasing risk for autism: a review and meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry 2012 May; 51(5).
Grodberg D, Weinger PM, Kolevzon A, Soorya L, Buxbaum JD. Brief report: the Autism Mental Status Examination: development of a brief autism-focused exam. Journal of autism and developmental disorders 2012 Mar; 42(3).
Girgis RR, Slifstein M, Xu X, Frankle WG, Anagnostou E, Wasserman S, Pepa L, Kolevzon A, Abi-Dargham A, Laruelle M, Hollander E. The 5-HT(2A) receptor and serotonin transporter in Asperger's disorder: A PET study with [¹¹C]MDL 100907 and [¹¹C]DASB. Psychiatry research 2011 Dec; 194(3).
Kolevzon A, Cai G, Soorya L, Takahashi N, Grodberg D, Kajiwara Y, Willner JP, Tryfon A, Buxbaum JD. Analysis of a purported SHANK3 mutation in a boy with autism: clinical impact of rare variant research in neurodevelopmental disabilities. Brain research 2011 Mar; 1380.
Bartz JA, Zaki J, Bolger N, Hollander E, Ludwig NN, Kolevzon A, Ochsner KN. Oxytocin selectively improves empathic accuracy. Psychological science 2010 Oct; 21(10).
Kolevzon A, Newcorn JH, Kryzak L, Chaplin W, Watner D, Hollander E, Smith CJ, Cook EH, Silverman JM. Relationship between whole blood serotonin and repetitive behaviors in autism. Psychiatry research 2010 Feb; 175(3).
Parikh MS, Kolevzon A, Hollander E. Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. Journal of child and adolescent psychopharmacology 2008 Apr; 18(2).
Kolevzon A, Gross R, Reichenberg A. Prenatal and perinatal risk factors for autism: a review and integration of findings. Archives of pediatrics & adolescent medicine 2007 Apr; 161(4).
- A Randomized, Double-Blind, 12-week, Parallel Group, Placebo-Controlled Study of the Efficacy and Safety of RO4917523 in Patients with Fragile X Syndrome
- A Randomized Double-Blind Placebo-Controlled Parallel-Group Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome
- Piloting Treatment with Insulin-Like Growth Factor-1 (IGF-1) in Phelan McDermid Syndrome
- Phelan-McDermid Syndrome: Insights into Synaptic Pathology and Novel Therapeutics in ASD
- Evidence-based Practices for Interventions to Improve the Health and Well-being of Children with Autism Spectrum Disorders
- A Randomized, Double-blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Children with Fragile X Syndrome
- Trichuris Suis Ova Treatment of Adult Autism Symptom Domains
- A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism
- A randomized, parallel-group, double-blind, placebo-controlled, safety and exploratory efficacy and pharmacokinetic study of R04917523 in pediatric patients with Fragile X Syndrome
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Kolevzon during 2013 and/or 2014. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Enzymotec, Ltd.; Gerson Lehrman Group
Scientific Advisory Board:
- Enzymotec, Ltd.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.